Seltene-Erden-Kooperation: Medallion Res. und Rare Earth Salts (Seite 39)

[commie]

Sieht leider erst mal nach Absturz aus heute ... ohne News ... -20%..
Mit den Blumen und der Umwelt kann es ja wohl kaum zu tun haben bei Medallion

[heesi]

Antwort auf Beitrag Nr.: 67.255.536 von Oginvest am 01.03.21 19:20:16

Merci, interessanter Artikel!

Dafür hat MDL doch hinsichtlich REE *DIE* Lösung für Abnehmer/Umweltverbände/Natives und US-Regierung:
OHNE Mining, mit Verarbeitung von bereits "ge-mine-ten" und im Überfluss vorhandenen Monazitsanden.

Diese Vorzüge von MDL müssten viel lauter, breiter und aggressiver publik gemacht werden; nicht nur bei Politik und Administration, sondern auch im Markt. D.h. deutlich mehr die PR-Werbetrommel rühren😉

[Oginvest]

To go electric, America needs more mines. Can it build them?

By Ernest Scheyder (Reuters) - Last September, in the arid hills of northern Nevada, a cluster of flowers found nowhere else on earth died mysteriously overnight.

Conservationists were quick to suspect ioneer Ltd, an Australian firm that wants to mine the lithium that lies beneath the flowers for use in electric vehicle (EV) batteries.

One conservation group alleged in a lawsuit that the flowers, known as Tiehm's buckwheat, were "dug up and destroyed." The rare plant posed a problem for ioneer because U.S. officials may soon add it to the Endangered Species List, which could scuttle the mining project.

Ioneer denies harming the flowers. Their cause of death remains hotly debated - as does the fate of the lithium mine.

The clash of environmental priorities underpinning the battle over Tiehm's buckwheat - conservation vs. green energy - is a microcosm of a much larger political quandary for the new administration of President Joe Biden, who has made big promises to environmentalists as well as labor groups and others who stand to benefit by boosting mining.

To please conservationists, Biden has vowed to set aside at least 30% of U.S. federal land and coastal areas for conservation, triple current levels.

But that aim could conflict with his promises to hasten the electrification of vehicles and to reduce the country's dependence on China for rare earths, lithium and other minerals needed for EV batteries. The administration has called the reliance on China a national security threat.

The administration will be forced into hard choices that anger one constituency or another.

"You can't have green energy without mining," Mark Senti, chief executive of Florida-based rare earth magnet company Advanced Magnet Lab Inc. "That's just the reality."

Rare earth magnets are used to make a range of consumer electronics as well as precision-guided missiles and other weapons.

Two sources familiar with White House deliberations on domestic mining told Reuters that Biden plans to allow mines that produce EV metals to be developed under existing environmental standards, rather than face a tightened process that would apply to mining for other materials, such as coal.

Biden is open to allowing more mines on federal land, the sources said, but won't give the industry carte blanche to dig everywhere. That will likely mean approval of mines for rare earths and lithium, though certain copper projects – including a proposed Arizona copper mine from Rio Tinto Plc opposed by Native Americans - are likely to face extra scrutiny, the sources said.

The White House declined to comment for this article.

DIGGING NEEDED

Demand for metals used in EV batteries is expected to rise sharply as automakers including Tesla Inc, BMW and General Motors plan major expansions of EV production. California, the biggest U.S. vehicle market, aims to entirely ban fossil fuel-powered engines by 2035.

Biden has promised to convert the entire U.S. government fleet - about 640,000 vehicles - to EVs. That plan alone could require a 12-fold increase in U.S. lithium production by 2030, according to Benchmark Minerals Intelligence, as well as increases in output of domestic copper, nickel and cobalt. Federal land is teeming with many of these EV metals, according to the U.S. Geological Survey.

"There is no way there's enough raw materials being produced right now to start replacing millions of gasoline-powered motor vehicles with EVs," said Lewis Black, CEO of Almonty Industries Inc, which mines the hardening metal tungsten in Portugal and South Korea.

Despite that shortage, proposed U.S. mines from Rio Tinto Ltd, BHP Group Ltd, Antofagasta Plc, Lithium Americas Corp, Glencore Plc and others are drawing stiff opposition from conservation groups. The projects would supply enough lithium for more than 5 million EV batteries and enough copper for more than 10,000 EVs each year.

Mining companies insist that federal lands can still be protected while the U.S. boosts output of minerals needed to accelerate the EV transition.

Former U.S. President Donald Trump and the mining industry "pushed the narrative that we need to mine everywhere and undercut environmental safeguards in order to build more batteries," said Drew McConville of The Wilderness Society, a conservation group. "We have confidence that the Biden administration is going to see through that false narrative."

Earthworks and other environmental groups are now lobbying automakers to only buy metals from mines deemed environmentally friendly by the Initiative for Responsible Mining Assurance (IRMA), a nonprofit group. BMW, Ford Motor Co and Daimler have agreed to abide by IRMA guidelines, and other automakers may follow suit.

PROJECTS AT RISK

Biden has not weighed in on two controversial copper mine projects in Minnesota's environmentally-sensitive Boundary Waters region from PolyMet Mining Corp and Antofagasta Plc's Twin Metals subsidiary.

Tom Vilsack - the secretary of agriculture, the department that oversees the Boundary Waters - has in the past opposed the Twin Metals project, arguing that it threatened wilderness and marshlands.

Deb Haaland, the new secretary of interior, the department that controls most federal land, previously voted for a bill that would have banned copper sulfide mining in northern Minnesota. That bill, authored by U.S. Representative Betty McCollum, a Minnesota Democrat, will be reintroduced this month, her aides told Reuters.

Conservationists nonetheless remain concerned that the appeal of copper for EVs and other renewable energy devices may help the mines ultimately get approved.

"If these were coal mines, I'd feel much more comfortable knowing they wouldn't be approved," said Pete Marshall of Friends of the Boundary Waters.

WORRIES ABOUT WILDLIFE, SACRED GROUNDS, FLOWERS

In Arizona, Biden promised Native Americans - whose votes helped him win the battleground state - that they would have a "seat at the table" if he defeated Trump. But he has yet to meet with them to discuss worries that Rio Tinto's Resolution proposed copper mine would destroy sacred sites considered home to religious deities.

Other controversial projects include Idaho's Stibnite proposed mine, from John Paulson-backed Perpetua Resources Corp, which is under fresh scrutiny by U.S. Environmental Protection Agency staff over fears it would pollute Native American fishing grounds. The mine would produce gold and antimony, used to make alloys for EV batteries.

In Nevada, the Department of Wildlife worries that the lithium mines planned by ioneer and Lithium Americas would harm trout, deer and pronghorn habitats. The Lithium Americas mine received federal approval last month, but ranchers have sued the U.S. government to reverse that decision.

"Renewable energy and electric cars aren't green if they destroy an important habitat and drive wildlife extinct," said Kelly Fuller, of the Western Watersheds Project, which opposes the Lithium Americas project.

In Nevada, the death of the Tiehm's buckwheat flowers at ioneer's proposed mine site remains a point of contention. The U.S. Fish and Wildlife Service has theorized that thirsty squirrels may have gnawed the roots of more than 17,000 flowers for water amid a drought in the state.

The Center for Biological Diversity, which opposes the mine, said there was evidence that humans destroyed the flowers. "The targeted nature of the damage, combined with the lack of feces, pawprints, hoofprints, or other evidence of wildlife suggest human involvement," the group said in a court filing.

The Fish and Wildlife Service is now set to rule this summer on whether the flower is an endangered species - a designation that would prevent development on much of the land ioneer is trying to mine.

Ioneer has hired scientists to move the flowers to a new site, though it's unclear if that process will succeed. "We can extract this lithium and also save this flower," said James Calaway, ioneer's chairman.

(Reporting by Ernest Scheyder; additional reporting by Trevor Hunnicutt; editing by Amran Abocar and Brian Thevenot)

Quelle: https://www.msn.com/en-gb/news/world/to-go-electric-america-…

[Oginvest]

China says domestic competition hurting rare earth prices

01.03.2021 - By Gabriel Crossley and Min Zhang

BEIJING (Reuters) - China's rare earths, a group of 17 minerals used in military equipment and consumer electronics, are being undersold due to "vicious competition" domestically and face low resource utilisation, the country's industry minister said on Monday.

Prices for some rare earths in China, such as praseodymium-neodymium (PrNd) - used in rare earth magnets - have spiked to multi-year highs this year amid strong demand from the electric vehicle sector.

However, prices for other rare earths mined simultaneously, such as cerium and lanthanum, used in catalysts for oil refining, remain depressed due to abundant supply.

"Our rare earths did not sell at the 'rare' price but sold at the 'earth' price... because of competitive bidding, which wasted the precious resource," Minister of Industry and Information Technology Xiao Yaqing said during a news briefing.

A heavy reliance on China, the world's top producer of rare earths, has led the United States to order a review of its supply chain for the minerals.

Shipments of rare earth magnets from China to the United States hit 585 tonnes in December, the highest since at least 2016, according to Chinese customs data. China's overall rare earth exports last year were the lowest since 2015 amid coronavirus-hit demand overseas.

China's industry ministry proposed in January tightening regulation of the rare earth sector, including a stipulation that importers and exporters abide by foreign trade and export control laws.

"Government should play a role in maintaining market order, loosen what can be loosened and control what should be controlled," said Xiao, who previously served as head of state-owned metals group Chinalco, the parent of one of China's biggest rare earth producers.

The minister said some companies were producing excessive amounts of rare earths, causing environmental issues and leading to low resource utilisation rates.

China raised its rare earth output quotas for the first half of 2021 to record levels.

Meanwhile, China lacks high-level rare earth products, Xiao said, adding the country "should learn from Japanese enterprises in this regard."

(Reporting by Gabriel Crossley; Writing by Se Young Lee and Min Zhang; additional reporting by Tom Daly; Editing by Gerry Doyle and Edmund Blair)

Quelle: https://www.msn.com/en-ca/money/other/china-says-domestic-co…

[Tirolesi]

[Tirolesi]

https://www.globenewswire.com/news-release/2021/02/24/218196…

[Tirolesi]

www.ubs.com/investmentresearch
This report has been prepared by UBS AG London Branch. ANALYST CERTIFICATION AND REQUIRED DISCLOSURES,
including information on the Quantitative Research Review published by UBS, begin on page 11. UBS does and seeks to
do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict
of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their
investment decision.
 Global Research 24 February 2021
Expert Call
Rare Earths: Will prices double again?
Rare Earths pricing bouncing back faster than expected due to supply anxiety
We hosted a call on Rare Earths with Daniel Morgan, our Australian mining analyst,
who covers Lynas (replay details below). There is significant interest in Rare Earths due
to trade tensions (China dominates supply) & due to the demand growth potential from
EVs/ wind power (note). Rare earth stocks include Lynas (Neutral) & MP Materials (n/r).
1) 17 Elements with Nd/ Pr dominant; 2) NdPr market to grow 300% by 2030
(1) Rare Earth is a term used for a collection of 17 chemical elements which are used in
small quantities in a large variety of industrial & technology applications. Rare earth
ores vary in grade up to ~10% with Lanthanum (La) & Cerium (Ce) typically abundant
(~60% volume); Neodymium (Nd) & Praseodymium (Pr) (used in magnets) are currently
the most valuable (~20% volume, 80-90% of revenue). Small quantities of various
elements are used in defence applications & strategically important. (2) Demand: we
expect NdPr demand to grow ~300% by 2030 (2020 ~30kt) driven by Electric Vehicle
demand (an EV typically has 1-2kg of NdPr in its motor); wind turbines have ~200kg of
NdPr & provide upside risk to UBSe demand.
3) China dominant supplier; 4) Trade tensions; 5) Prices doubled since mid-20
(3) Supply: China currently produces ~70% of global rare earth supply (pre-1990s US
was dominant) with Lynas (Australia) & MP Materials (US) each ~15%; China currently
processes ~90% of supply with MP exporting concentrate to China for separation &
Lynas processing ~60% in Malaysia & ~40% (heavy rare earths) in China; this will
moderate with MP restarting its refining plant in California in 2022 & Lynas set to build
a processing plant in Texas (news). Processing rare earths is notoriously challenging.
There is currently a modest surplus in China, which produces to its semi-annual quota
(which at 81kt in 1H21 is up 28% y/y). (4) Trade: China imposed strict rare earth export
quotas in 2010 but this was blocked by the WTO (news); exports have fallen sharply in
2020 (part due to Covid) & China has said it may cut exports/ ban exports of refining
technology on security grounds (news). (5) Prices: NdPr prices have doubled since mid-
20 driven mainly by supply anxiety & some demand pick-up. We forecast NdPr prices of
$60/kg in 2021 (spot ~$67/kg), lifting to ~$100/kg in 2024 vs incentive price of
$60/kg; we see potential for non-China supply to attract a price premium over time.
Equities
Global
Basic Materials
Myles Allsop
Analyst
[e-mail]
[phone]
Daniel Morgan
Analyst
[e-mail]
[phone]
Daniel Major
Analyst
[e-mail]
[phone]
Andrew Stott
Analyst
[e-mail]
[phone]
Andreas Bokkenheuser
Analyst
[e-mail]
[phone]
Expert Call 24 February 2021
 2
We hosted a call with Daniel Morgan, our Australian mid-cap mining analyst,
who covers Lynas Corporation, the largest producer of Rare Earths outside
China. Daniel provided a 101 on Rare Earths and discussed the implications of
China's proposal to limit exports. The supply and demand outlook is also set
out in the note below.
Battery Raw Materials "From mine to motor - can supply keep pace with
demand?"
The replay details are:
UK Phone: [phone] or 0800 032 9687
Replay Global Access URL: LINK
Passcode: 93244294#
Figure 1: What are Rare Earths?
Source: Lynas, UBS. LREE is Light Rare Earth Elements, HREE is Heavy Rare Earth Elements
Expert Call 24 February 2021
 3
Figure 2: US- China Rare Earth Trade Tensions
Source: UBS
Figure 3: How are Rare Earths used?
Source: USGS, Company Filings, UBS Estimates. Note, estimate of rare earths shown in the table is our estimation of various deposits as to the proportion of rare earths
within rare earth oxides
Expert Call 24 February 2021
 4
Figure 4: Strong Demand Growth forecast for NdPr from EVs
Source: GWEC, Company Filings, UBS Estimates
Figure 5: Rare Earths Supply - China Dominates
Source: USGS, Company Filings, UBS estimates
Expert Call 24 February 2021
 5
Figure 6: Rare Earths Supply - China Constraints
Source: China Customs, Bloomberg
Figure 7: Most of the Magnet Supply Chain is in China too
Source: Public Filings
Expert Call 24 February 2021
 6
Figure 8: Lynas Production Chain Now
Source: Public Filings
Figure 9: Lynas Production Chain in Future
Source: Public Filings
Expert Call 24 February 2021
 7
Figure 10: Rare Earths Supply - Global Resources
Source: USGS
Figure 11: Rare Earths Supply - Global Resources
Source: Company Filings
Expert Call 24 February 2021
 8
Figure 12: Rare Earths Pricing
Source: Asian Metals, Bloomberg, UBS estimates
Figure 13: NdPr Prices are still well below the 2011 spike
Source: Asian Metals, Bloomberg
Expert Call 24 February 2021
 9
Figure 14: Ndpr Incentive Pricing- we estimate ~ US$60/kg
Source: Company Filings, UBS Research
Figure 15: NdPr tightness to emerge from EVs
Source: USGS, Company Filings, UBS estimates
Expert Call 24 February 2021
 10
Figure 16: Lynas Earnings Estimates
Source: UBS estimates
Valuation Method and Risk Statement
Investment risk inherent in the resource sector includes, but it is not limited to,
movements in commodity price and currency which may differ materially from the
assumption used in this report. Furthermore, the sector is subject to political,
financial and operational risks, each of which has the potential to significantly
impact company/industry performance.
Our price target for Lynas is based on an NPV estimate.
Expert Call 24 February 2021
 11
Required Disclosures
This report has been prepared by UBS AG London Branch, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and
affiliates are referred to herein as UBS.
For information on the ways in which UBS manages conflicts and maintains independence of its research product; historical
performance information; certain additional disclosures concerning UBS research recommendations; and terms and
conditions for certain third party data used in research report, please visit www.ubs.com/disclosures. The figures contained
in performance charts refer to the past; past performance is not a reliable indicator of future results. Additional information
will be made available upon request. UBS Securities Co. Limited is licensed to conduct securities investment consultancy
businesses by the China Securities Regulatory Commission. UBS acts or may act as principal in the debt securities (or in
related derivatives) that may be the subject of this report. This recommendation was finalized on: 23 February 2021 11:22
PM GMT. UBS has designated certain Research department members as Derivatives Research Analysts where those
department members publish research principally on the analysis of the price or market for a derivative, and provide
information reasonably sufficient upon which to base a decision to enter into a derivatives transaction. Where Derivatives
Research Analysts co-author research reports with Equity Research Analysts or Economists, the Derivatives Research Analyst
is responsible for the derivatives investment views, forecasts, and/or recommendations. Quantitative Research Review:
UBS publishes a quantitative assessment of its analysts' responses to certain questions about the likelihood of an occurrence
of a number of short term factors in a product known as the 'Quantitative Research Review'. Views contained in this
assessment on a particular stock reflect only the views on those short term factors which are a different timeframe to the
12-month timeframe reflected in any equity rating set out in this note. For the latest responses, please click
https://neo.ubs.com/quantitative, or speak to your UBS sales representative for access to the report.
Analyst Certification:Each research analyst primarily responsible for the content of this research report, in whole or in part,
certifies that with respect to each security or issuer that the analyst covered in this report: (1) all of the views expressed
accurately reflect his or her personal views about those securities or issuers and were prepared in an independent manner,
including with respect to UBS, and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to
the specific recommendations or views expressed by that research analyst in the research report.
UBS Investment Research: Global Equity Rating Definitions
12-Month Rating Definition Coverage1 IB Services2
Buy FSR is > 6% above the MRA. 51% 31%
Neutral FSR is between -6% and 6% of the MRA. 37% 29%
Sell FSR is > 6% below the MRA. 12% 18%
Short-Term Rating Definition Coverage3 IB Services4
Buy
Stock price expected to rise within three months from the time
the rating was assigned because of a specific catalyst or event. <1% <1%
Sell
Stock price expected to fall within three months from the time
the rating was assigned because of a specific catalyst or event. <1% <1%
Source: UBS. Rating allocations are as of 31 December 2020.
1:Percentage of companies under coverage globally within the 12-month rating category.
2:Percentage of companies within the 12-month rating category for which investment banking (IB) services were provided
within the past 12 months.
3:Percentage of companies under coverage globally within the Short-Term rating category.
4:Percentage of companies within the Short-Term rating category for which investment banking (IB) services were provided
within the past 12 months.
KEY DEFINITIONS:Forecast Stock Return (FSR) is defined as expected percentage price appreciation plus gross dividend
yield over the next 12 months. In some cases, this yield may be based on accrued dividends. Market Return Assumption
(MRA) is defined as the one-year local market interest rate plus 5% (a proxy for, and not a forecast of, the equity risk
premium). Under Review (UR) Stocks may be flagged as UR by the analyst, indicating that the stock's price target and/or
rating are subject to possible change in the near term, usually in response to an event that may affect the investment case
or valuation. Short-Term Ratings reflect the expected near-term (up to three months) performance of the stock and do not
reflect any change in the fundamental view or investment case. Equity Price Targets have an investment horizon of 12
months.
Expert Call 24 February 2021
 12
EXCEPTIONS AND SPECIAL CASES:UK and European Investment Fund ratings and definitions are: Buy: Positive on
factors such as structure, management, performance record, discount; Neutral: Neutral on factors such as structure,
management, performance record, discount; Sell: Negative on factors such as structure, management, performance record,
discount. Core Banding Exceptions (CBE): Exceptions to the standard +/-6% bands may be granted by the Investment
Review Committee (IRC). Factors considered by the IRC include the stock's volatility and the credit spread of the respective
company's debt. As a result, stocks deemed to be very high or low risk may be subject to higher or lower bands as they
relate to the rating. When such exceptions apply, they will be identified in the Company Disclosures table in the relevant
research piece.
Research analysts contributing to this report who are employed by any non-US affiliate of UBS Securities LLC are not
registered/qualified as research analysts with FINRA. Such analysts may not be associated persons of UBS Securities LLC and
therefore are not subject to the FINRA restrictions on communications with a subject company, public appearances, and
trading securities held by a research analyst account. The name of each affiliate and analyst employed by that affiliate
contributing to this report, if any, follows.
UBS AG London Branch: Myles Allsop; Daniel Major; Andrew Stott. UBS Securities Australia Ltd: Daniel Morgan. UBS
Securities LLC: Andreas Bokkenheuser.
Company Disclosures
Company Name Reuters 12-month rating Short-term rating Price Price date
Lynas Corporation LYC.AX Neutral N/A A$5.80 23 Feb 2021
Source: UBS. All prices as of local market close.
Ratings in this table are the most current published ratings prior to this report. They may be more recent than the stock
pricing date
Unless otherwise indicated, please refer to the Valuation and Risk sections within the body of this report. For a complete set
of disclosure statements associated with the companies discussed in this report, including information on valuation and risk,
please contact UBS Securities LLC, 1285 Avenue of Americas, New York, NY 10019, USA, Attention: Investment Research.
Lynas Corporation (A$)
01-Dec-17
01-Feb-18
01-Apr-18
01-Jun-18
01-Aug-18
01-Oct-18
01-Dec-18
01-Feb-19
01-Apr-19
01-Jun-19
01-Aug-19
01-Oct-19
01-Dec-19
01-Feb-20
01-Apr-20
01-Jun-20
01-Aug-20
01-Oct-20
01-Dec-20
01-Feb-21
0.00
2.00
4.00
6.00
8.00
Price Target (A$) Stock Price (A$)
Buy
Neutral
No Rating
Expert Call 24 February 2021
 13
Date Stock Price (A$) Price Target (A$) Rating
2017-11-23 2.1 - No Rating
2018-07-23 2.14 3.3 Buy
2018-09-06 1.89 3.2 Buy
2018-10-25 1.7 3.1 Buy
2018-12-06 1.67 2.9 Buy
2019-02-28 1.76 2.8 Buy
2019-03-26 2.1 - No Rating
2019-08-28 2.32 2.8 Buy
2019-08-29 2.36 3.0 Buy
2020-02-28 1.85 2.8 Buy
2020-03-27 1.27 2.7 Buy
2020-07-22 2.08 2.8 Buy
2020-08-17 2.61 3.0 Buy
2020-10-22 2.91 3.4 Buy
2020-11-24 3.53 4.05 Buy
2020-12-10 4.01 4.3 Neutral
Source: UBS; as of 23 Feb 2021
Expert Call 24 February 2021
 14
The Disclaimer relevant to Global Wealth Management clients follows the Global
Disclaimer.
Global Disclaimer
This document has been prepared by UBS AG London Branch, an affiliate of UBS AG. UBS AG, its subsidiaries, branches and affiliates are referred to herein as UBS.
This Document is provided solely to recipients who are expressly authorized by UBS to receive it. If you are not so authorized you must immediately
destroy the Document.
Global Research is provided to our clients through UBS Neo, and in certain instances, UBS.com and any other system or distribution method specifically identified in one
or more communications distributed through UBS Neo or UBS.com (each a system) as an approved means for distributing Global Research. It may also be made available
through third party vendors and distributed by UBS and/or third parties via e-mail or alternative electronic means. The level and types of services provided by Global
Research to a client may vary depending upon various factors such as a client's individual preferences as to the frequency and manner of receiving communications, a
client's risk profile and investment focus and perspective (e.g., market wide, sector specific, long-term, short-term, etc.), the size and scope of the overall client
relationship with UBS and legal and regulatory constraints.
All Global Research is available on UBS Neo. Please contact your UBS sales representative if you wish to discuss your access to UBS Neo.
When you receive Global Research through a system, your access and/or use of such Global Research is subject to this Global Research Disclaimer and to the UBS Neo
Platform Use Agreement (the "Neo Terms") together with any other relevant terms of use governing the applicable System.
When you receive Global Research via a third party vendor, e-mail or other electronic means, you agree that use shall be subject to this Global Research Disclaimer, the
Neo Terms and where applicable the UBS Investment Bank terms of business (https://www.ubs.com/global/en/investment-bank/regulatory.htm… and to UBS's Terms of
Use/Disclaimer (http://www.ubs.com/global/en/legalinfo2/disclaimer.html). In addition, you consent to UBS processing your personal data and using cookies in
accordance with our Privacy Statement (http://www.ubs.com/global/en/legalinfo2/privacy.html) and cookie notice
(http://www.ubs.com/global/en/homepage/cookies/cookie-managem…
If you receive Global Research, whether through a System or by any other means, you agree that you shall not copy, revise, amend, create a derivative
work, provide to any third party, or in any way commercially exploit any UBS research provided via Global Research or otherwise, and that you shall not
extract data from any research or estimates provided to you via Global Research or otherwise, without the prior written consent of UBS.
This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or
resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or
would subject UBS to any registration or licensing requirement within such jurisdiction.
This document is a general communication and is educational in nature; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial
instruments or to participate in any particular trading strategy. Nothing in this document constitutes a representation that any investment strategy or recommendation is
suitable or appropriate to an investor’s individual circumstances or otherwise constitutes a personal recommendation. By providing this document, none of UBS or its
representatives has any responsibility or authority to provide or have provided investment advice in a fiduciary capacity or otherwise. Investments involve risks, and
investors should exercise prudence and their own judgment in making their investment decisions. None of UBS or its representatives is suggesting that the recipient or
any other person take a specific course of action or any action at all. By receiving this document, the recipient acknowledges and agrees with the intended purpose
described above and further disclaims any expectation or belief that the information constitutes investment advice to the recipient or otherwise purports to meet the
investment objectives of the recipient. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of
investors.
Options, structured derivative products and futures (including OTC derivatives) are not suitable for all investors. Trading in these instruments is considered risky and may
be appropriate only for sophisticated investors. Prior to buying or selling an option, and for the complete risks relating to options, you must receive a copy of "The
Characteristics and Risks of Standardized Options." You may read the document at http://www.theocc.com/publications/risks/riskchap1.jsp or ask your salesperson for a
copy. Various theoretical explanations of the risks associated with these instruments have been published. Supporting documentation for any claims, comparisons,
recommendations, statistics or other technical data will be supplied upon request. Past performance is not necessarily indicative of future results. Transaction costs may
be significant in option strategies calling for multiple purchases and sales of options, such as spreads and straddles. Because of the importance of tax considerations to
many options transactions, the investor considering options should consult with his/her tax advisor as to how taxes affect the outcome of contemplated options
transactions.
Mortgage and asset-backed securities may involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market
conditions. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument referred to in the document. For
investment advice, trade execution or other enquiries, clients should contact their local sales representative.
The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily
a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising
out of the use of all or any of the Information.
Prior to making any investment or financial decisions, any recipient of this document or the information should take steps to understand the risk and return of the
investment and seek individualized advice from his or her personal financial, legal, tax and other professional advisors that takes into account all the particular facts and
circumstances of his or her investment objectives.
Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no
representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or
theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.
No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in any
materials to which this document relates (the "Information"), except with respect to Information concerning UBS. The Information is not intended to be a complete
statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any
opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups, personnel or
other representative of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions
provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. In no
circumstances may this document or any of the Information (including any forecast, value, index or other calculated amount ("Values")) be used for any of the following
purposes:
(i) valuation or accounting purposes;
(ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
(iii) to measure the performance of any financial instrument including, without limitation, for the purpose of tracking the return or performance of any Value or of
defining the asset allocation of portfolio or of computing performance fees.
By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for
any of the above purposes or otherwise rely upon this document or any of the Information.
UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS
relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS and among its subsidiaries, branches and affiliates. For further
information on the ways in which UBS manages conflicts and maintains independence of its research products, historical performance information and certain additional
disclosures concerning UBS research recommendations, please visit www.ubs.com/disclosures.
Expert Call 24 February 2021
 15
Research will initiate, update and cease coverage solely at the discretion of UBS Research Management, which will also have sole discretion on the timing and frequency
of any published research product. The analysis contained in this document is based on numerous assumptions. All material information in relation to published research
reports, such as valuation methodology, risk statements, underlying assumptions (including sensitivity analysis of those assumptions), ratings history etc. as required by
the Market Abuse Regulation, can be found on UBS Neo. Different assumptions could result in materially different results.
The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering,
applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other
areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior
management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the
revenues of UBS and/or its divisions as a whole, of which investment banking, sales and trading are a part, and UBS's subsidiaries, branches and affiliates as a whole.
For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or
liquidity provider (in accordance with the interpretation of these terms under English law or, if not carried out by UBS in the UK the law of the relevant jurisdiction in
which UBS determines it carries out the activity) in the financial instruments of the issuer save that where the activity of liquidity provider is carried out in accordance
with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in this document. For financial
instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in the US in accordance with
the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued a warrant the value of
which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or short positions, trade as
principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions expressed in this document.
Within the past 12 months UBS AG, its affiliates or subsidiaries may have received or provided investment services and activities or ancillary services as per MiFID II which
may have given rise to a payment or promise of a payment in relation to these services from or to this company.
Where Global Research refers to "UBS Evidence Lab Inside" or has made use of data provided by UBS Evidence Lab you understand that UBS Evidence Lab is a separate
department to Global Research and that UBS Evidence Lab does not provide research, investment recommendations or advice. UBS Evidence Lab may provide services to
other internal and external clients.
United Kingdom: This material is distributed by UBS AG, London Branch to persons who are eligible counterparties or professional clients. UBS AG, London Branch is
authorised by the Prudential Regulation Authority and subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation
Authority. Europe: Except as otherwise specified herein, these materials are distributed by UBS Europe SE, a subsidiary of UBS AG, to persons who are eligible
counterparties or professional clients (as detailed in the Bundesanstalt fur Finanzdienstleistungsaufsicht (BaFin) Rules and according to MIFID) and are only available to
such persons. The information does not apply to, and should not be relied upon by, retail clients. UBS Europe SE is authorised by the European Central Bank (ECB) and
regulated by the BaFin and the ECB. Germany: Where an analyst of UBS Europe SE has contributed to this document, the document is also deemed to have been
prepared by UBS Europe SE. In all cases it is distributed by UBS Europe SE and UBS AG, London Branch. Luxembourg, the Netherlands, Belgium and Ireland: Where
an analyst of UBS Europe SE has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE. In all cases it is distributed by
UBS Europe SE and UBS AG, London Branch. Turkey: Distributed by UBS AG, London Branch. No information in this document is provided for the purpose of offering,
marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be considered as an offer
made or to be made to residents of the Republic of Turkey. UBS AG, London Branch is not licensed by the Turkish Capital Market Board under the provisions of the
Capital Market Law (Law No. 6362). Accordingly, neither this document nor any other offering material related to the instruments/services may be utilized in connection
with providing any capital market services to persons within the Republic of Turkey without the prior approval of the Capital Market Board. However, according to article
15 (d) (ii) of the Decree No. 32, there is no restriction on the purchase or sale of the securities abroad by residents of the Republic of Turkey. Poland: Distributed by UBS
Europe SE (spolka z ograniczona odpowiedzialnoscia) Oddzial w Polsce regulated by the Polish Financial Supervision Authority. Where an analyst of UBS Europe SE
(spolka z ograniczona odpowiedzialnoscia) Oddzial w Polsce has contributed to this document, the document is also deemed to have been prepared by UBS Europe SE
(spolka z ograniczona odpowiedzialnoscia) Oddzial w Polsce. Russia: Prepared and distributed by UBS Bank (OOO). "Should not be construed as an individual
Investment Recommendation for the purpose of the Russian Law" - Federal Law #39-FZ ON THE SECURITIES MARKET Articles 6.1-6.2.Switzerland: Distributed by UBS
AG to persons who are institutional investors only. UBS AG is regulated by the Swiss Financial Market Supervisory Authority (FINMA). Italy: Prepared by UBS Europe SE
and distributed by UBS Europe SE and UBS Europe SE, Italy Branch. Where an analyst of UBS Europe SE, Italy Branch has contributed to this document, the document is
also deemed to have been prepared by UBS Europe SE, Italy Branch.South Africa: Distributed by UBS South Africa (Pty) Limited (Registration No. 1995/011140/07), an
authorised user of the JSE and an authorised Financial Services Provider (FSP 7328). Saudi Arabia: This document has been issued by UBS AG (and/or any of its
subsidiaries, branches or affiliates), a public company limited by shares, incorporated in Switzerland with its registered offices at Aeschenvorstadt 1, CH-4051 Basel and
Bahnhofstrasse 45, CH-8001 Zurich. This publication has been approved by UBS Saudi Arabia (a subsidiary of UBS AG), a Saudi closed joint stock company incorporated
in the Kingdom of Saudi Arabia under commercial register number 1010257812 having its registered office at Tatweer Towers, P.O. Box 75724, Riyadh 11588, Kingdom
of Saudi Arabia. UBS Saudi Arabia is authorized and regulated by the Capital Market Authority to conduct securities business under license number 08113-37. UAE /
Dubai: The information distributed by UBS AG Dubai Branch is only intended for Professional Clients and/or Market Counterparties, as classified under the DFSA
rulebook. No other person should act upon this material/communication. The information is not for further distribution within the United Arab Emirates. UBS AG Dubai
Branch is regulated by the DFSA in the DIFC. UBS is not licensed to provide banking services in the UAE by the Central Bank of the UAE, nor is it licensed by the UAE
Securities and Commodities Authority. Israel: This Material is distributed by UBS AG, London Branch. UBS Securities Israel Ltd is a licensed Investment Marketer that is
supervised by the Israel Securities Authority (ISA). UBS AG, London Branch and its affiliates incorporated outside Israel are not licensed under the Israeli Advisory Law.
UBS may engage among others in issuance of Financial Assets or in distribution of Financial Assets of other issuers for fees or other benefits. UBS AG, London Branch
and its affiliates may prefer various Financial Assets to which they have or may have an Affiliation (as such term is defined under the Israeli Advisory Law). Nothing in this
Material should be considered as investment advice under the Israeli Advisory Law. This Material is being issued only to and/or is directed only at persons who are Eligible
Clients within the meaning of the Israeli Advisory Law, and this Material must not be furnished to, relied on or acted upon by any other persons. United States:
Distributed to US persons by either UBS Securities LLC or by UBS Financial Services Inc., subsidiaries of UBS AG; or by a group, subsidiary or affiliate of UBS AG that is not
registered as a US broker-dealer (a ‘non-US affiliate’) to major US institutional investors only. UBS Securities LLC or UBS Financial Services Inc. accepts responsibility for
the content of a report prepared by another non-US affiliate when distributed to US persons by UBS Securities LLC or UBS Financial Services Inc. All transactions by a US
person in the securities mentioned in this report must be effected through UBS Securities LLC or UBS Financial Services Inc., and not through a non-US affiliate. UBS
Securities LLC is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities Exchange Act (the
"Municipal Advisor Rule"), and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of the Municipal
Advisor Rule. Canada: Distributed by UBS Securities Canada Inc., a registered investment dealer in Canada and a Member-Canadian Investor Protection Fund, or by
another affiliate of UBS AG that is registered to conduct business in Canada or is otherwise exempt from registration. Brazil: Except as otherwise specified herein, this
material is prepared by UBS Brasil CCTVM S.A.¹ to persons who are eligible investors residing in Brazil, which are considered to be Investidores Profissionais, as
designated by the applicable regulation, mainly the CVM Instruction No. 539 from the 13th of November 2013 (determines the duty to verify the suitability of products,
services and transactions with regards to the client´s profile). ¹UBS Brasil CCTVM S.A. is a subsidiary of UBS BB Servicos de Assessoria Financeira e Participacoes S.A.
(“UBS BB”). UBS BB is an association between UBS AG and Banco do Brasil, of which UBS AG is the majority owner. Mexico: This report has been distributed and
prepared by UBS Casa de Bolsa, S.A. de C.V., a subsidiary of UBS AG. This document is intended for distribution to institutional or sophisticated investors only. Research
reports only reflect the views of the analysts responsible for the report. Analysts do not receive any compensation from the persons or entities different from UBS Casa
de Bolsa, S.A. de C.V., or different from entities belonging to the same financial group or business group of such Hong Kong: Distributed by UBS Securities Asia
Limited. Please contact local licensed persons of UBS Securities Asia Limited in respect of any matters arising from, or in connection with, the analysis or document
Singapore: Distributed by UBS Securities Pte. Ltd. [MCI (P) 003/08/2020 and Co. Reg. No.: 198500648C] or UBS AG, Singapore Branch. Please contact UBS Securities
Pte. Ltd., an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110); or UBS AG, Singapore Branch, an exempt financial adviser under the
Singapore Financial Advisers Act (Cap. 110) and a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of
Singapore, in respect of any matters arising from, or in connection with, the analysis or document. The recipients of this document represent and warrant that they are
accredited and institutional investors as defined in the Securities and Futures Act (Cap. 289). Japan: Distributed by UBS Securities Japan Co., Ltd. to professional
investors (except as otherwise permitted). Where this report has been prepared by UBS Securities Japan Co., Ltd., UBS Securities Japan Co., Ltd. is the author, publisher
and distributor of the report. Distributed by UBS AG, Tokyo Branch to Professional Investors (except as otherwise permitted) in relation to foreign exchange and other
banking businesses when relevant. Australia: Clients of UBS AG: Distributed by UBS AG (ABN 47 088 129 613 and holder of Australian Financial Services License No.
231087). Clients of UBS Securities Australia Ltd: Distributed by UBS Securities Australia Ltd (ABN 62 008 586 481 and holder of Australian Financial Services License No.
231098). This Document contains general information and/or general advice only and does not constitute personal financial product advice. As such, the Information in
this document has been prepared without taking into account any investor’s objectives, financial situation or needs, and investors should, before acting on the
Information, consider the appropriateness of the Information, having regard to their objectives, financial situation and needs. If the Information contained in this
Expert Call 24 February 2021
 16
document relates to the acquisition, or potential acquisition of a particular financial product by a ‘Retail’ client as defined by section 761G of the Corporations Act 2001
where a Product Disclosure Statement would be required, the retail client should obtain and consider the Product Disclosure Statement relating to the product before
making any decision about whether to acquire the product. New Zealand: Distributed by UBS New Zealand Ltd. UBS New Zealand Ltd is not a registered bank in New
Zealand. You are being provided with this UBS publication or material because you have indicated to UBS that you are a “wholesale client” within the meaning of
section 5C of the Financial Advisers Act 2008 of New Zealand (Permitted Client). This publication or material is not intended for clients who are not Permitted Clients
(non-permitted Clients). If you are a non-permitted Client you must not rely on this publication or material. If despite this warning you nevertheless rely on this
publication or material, you hereby (i) acknowledge that you may not rely on the content of this publication or material and that any recommendations or opinions in
such this publication or material are not made or provided to you, and (ii) to the maximum extent permitted by law (a) indemnify UBS and its associates or related
entities (and their respective Directors, officers, agents and Advisors) (each a ‘Relevant Person’) for any loss, damage, liability or claim any of them may incur or suffer as
a result of, or in connection with, your unauthorised reliance on this publication or material and (b) waive any rights or remedies you may have against any Relevant
Person for (or in respect of) any loss, damage, liability or claim you may incur or suffer as a result of, or in connection with, your unauthorised reliance on this publication
or material. Korea: Distributed in Korea by UBS Securities Pte. Ltd., Seoul Branch. This report may have been edited or contributed to from time to time by affiliates of
UBS Securities Pte. Ltd., Seoul Branch. This material is intended for professional/institutional clients only and not for distribution to any retail clients. Malaysia: This
material is authorized to be distributed in Malaysia by UBS Securities Malaysia Sdn. Bhd (Capital Markets Services License No.: CMSL/A0063/2007). This material is
intended for professional/institutional clients only and not for distribution to any retail clients. India: Distributed by UBS Securities India Private Ltd. (Corporate Identity
Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone: [phone]. It
provides brokerage services bearing SEBI Registration Number: INZ000259830; merchant banking services bearing SEBI Registration Number: INM000010809 and
Research Analyst services bearing SEBI Registration Number: INH000001204. UBS AG, its affiliates or subsidiaries may have debt holdings or positions in the subject
Indian company/companies. Within the past 12 months, UBS AG, its affiliates or subsidiaries may have received compensation for non-investment banking securitiesrelated
services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a client/clients of UBS AG, its
affiliates or subsidiaries during the 12 months preceding the date of distribution of the research report with respect to investment banking and/or non-investment
banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at:
http://www.ubs.com/global/en/about_ubs/investor_relations/an… Except as otherwise specified herein, this material may not be distributed in
Taiwan. Information and material on securities/instruments that are traded in a Taiwan organized exchange is deemed to be issued and distributed by UBS Securities Pte.
LTD., Taipei Branch, which is licensed and regulated by Taiwan Financial Supervisory Commission. Save for securities/instruments that are traded in a Taiwan organized
exchange, this material should not constitute "recommendation" to clients or recipients in Taiwan for the covered companies or any companies mentioned in this
document. No portion of the document may be reproduced or quoted by the press or any other person without authorisation from UBS. Indonesia: This report is being
distributed by PT UBS Sekuritas Indonesia and is delivered by its licensed employee(s), including marketing/sales person, to its client. PT UBS Sekuritas Indonesia, having
its registered office at Sequis Tower Level 22 unit 22-1,Jl.Jend. Sudirman, kav.71, SCBD lot 11B, Jakarta 12190, Indonesia, is a subsidiary company of UBS AG and
licensed under Capital Market Law no. 8 year 1995, a holder of broker-dealer and underwriter licenses issued by the Capital Market and Financial Institution Supervisory
Agency (now Otoritas Jasa Keuangan/OJK). PT UBS Sekuritas Indonesia is also a member of Indonesia Stock Exchange and supervised by Otoritas Jasa Keuangan (OJK).
Neither this report nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens except in compliance with applicable Indonesian capital market laws
and regulations. This report is not an offer of securities in Indonesia and may not be distributed within the territory of the Republic of Indonesia or to Indonesian citizens
in circumstance which constitutes an offering within the meaning of Indonesian capital market laws and regulations.
The disclosures contained in research documents produced by UBS AG, London Branch or UBS Europe SE shall be governed by and construed in accordance with English
law.
UBS specifically prohibits the redistribution of this document in whole or in part without the written permission of UBS and in any event UBS accepts no liability
whatsoever for any redistribution of this document or its contents or the actions of third parties in this respect. Images may depict objects or elements that are protected
by third party copyright, trademarks and other intellectual property rights. © UBS 2021. The key symbol and UBS are among the registered and unregistered trademarks
of UBS. All rights reserved.
Global Wealth Management Disclaimer
You receive this document in your capacity as a client of UBS Global Wealth Management. This publication has been distributed to you by UBS Switzerland AG
(regulated by FINMA in Switzerland) or its affiliates ("UBS") with whom you have a banking relationship with. The full name of the distributing affiliate and its
competent authority can be found in the country-specific disclaimer at the end of this document.
The date and time of the first dissemination of this publication is the same as the date and time of its publication.
Risk information:
You agree that you shall not copy, revise, amend, create a derivative work, provide to any third party, or in any way commercially exploit any UBS research, and that you
shall not extract data from any research or estimates, without the prior written consent of UBS.
This document is for distribution only as may be permitted by law. It is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or
resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or
would subject UBS to any registration or licensing requirement within such jurisdiction.
This document is a general communication and is educational in nature; it is not an advertisement nor is it a solicitation or an offer to buy or sell any financial
instruments or to participate in any particular trading strategy. Nothing in this document constitutes a representation that any investment strategy or recommendation is
suitable or appropriate to an investor’s individual circumstances or otherwise constitutes a personal recommendation. By providing this document, none of UBS or its
representatives has any responsibility or authority to provide or have provided investment advice in a fiduciary capacity or otherwise. Investments involve risks, and
investors should exercise prudence and their own judgment in making their investment decisions. None of UBS or its representatives is suggesting that the recipient or
any other person take a specific course of action or any action at all. By receiving this document, the recipient acknowledges and agrees with the intended purpose
described above and further disclaims any expectation or belief that the information constitutes investment advice to the recipient or otherwise purports to meet the
investment objectives of the recipient. The financial instruments described in the document may not be eligible for sale in all jurisdictions or to certain categories of
investors.
Options, derivative products and futures are not suitable for all investors, and trading in these instruments is considered risky. Mortgage and asset-backed securities may
involve a high degree of risk and may be highly volatile in response to fluctuations in interest rates or other market conditions. Foreign currency rates of exchange may
adversely affect the value, price or income of any security or related instrument referred to in the document. For investment advice, trade execution or other enquiries,
clients should contact their local sales representative.
The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Past performance is not necessarily
a guide to future performance. Neither UBS nor any of its directors, employees or agents accepts any liability for any loss (including investment loss) or damage arising
out of the use of all or any of the information (as defined below).
Prior to making any investment or financial decisions, any recipient of this document or the information should take steps to understand the risk and return of the
investment and seek individualized advice from his or her personal financial, legal, tax and other professional advisors that takes into account all the particular facts and
circumstances of his or her investment objectives.
Any prices stated in this document are for information purposes only and do not represent valuations for individual securities or other financial instruments. There is no
representation that any transaction can or could have been effected at those prices, and any prices do not necessarily reflect UBS's internal books and records or
theoretical model-based valuations and may be based on certain assumptions. Different assumptions by UBS or any other source may yield substantially different results.
No representation or warranty, either expressed or implied, is provided in relation to the accuracy, completeness or reliability of the information contained in any
materials to which this document relates (the "Information"), except with respect to Information concerning UBS. The Information is not intended to be a complete
statement or summary of the securities, markets or developments referred to in the document. UBS does not undertake to update or keep current the Information. Any
opinions expressed in this document may change without notice and may differ or be contrary to opinions expressed by other business areas or groups, personnel or
other representative of UBS. Any statements contained in this report attributed to a third party represent UBS's interpretation of the data, information and/or opinions
provided by that third party either publicly or through a subscription service, and such use and interpretation have not been reviewed by the third party. In no
Expert Call 24 February 2021
 17
circumstances may this document or any of the Information (including any forecast, value, index or other calculated amount ("Values")) be used for any of the following
purposes:
(i) valuation or accounting purposes;
(ii) to determine the amounts due or payable, the price or the value of any financial instrument or financial contract; or
(iii) to measure the performance of any financial instrument including, without limitation, for the purpose of tracking the return or performance of any Value or of
defining the asset allocation of portfolio or of computing performance fees.
By receiving this document and the Information you will be deemed to represent and warrant to UBS that you will not use this document or any of the Information for
any of the above purposes or otherwise rely upon this document or any of the Information.
UBS has policies and procedures, which include, without limitation, independence policies and permanent information barriers, that are intended, and upon which UBS
relies, to manage potential conflicts of interest and control the flow of information within divisions of UBS (including between Global Wealth Management and UBS
Global Research) and among its subsidiaries, branches and affiliates. For further information on the ways in which UBS manages conflicts and maintains independence of
its research products, historical performance information and certain additional disclosures concerning UBS research recommendations, please visit
www.ubs.com/disclosures.
Research will initiate, update and cease coverage solely at the discretion of research management, which will also have sole discretion on the timing and frequency of
any published research product. The analysis contained in this document is based on numerous assumptions. Different assumptions could result in materially different
results.
The analyst(s) responsible for the preparation of this document may interact with trading desk personnel, sales personnel and other parties for the purpose of gathering,
applying and interpreting market information. UBS relies on information barriers to control the flow of information contained in one or more areas within UBS into other
areas, units, groups or affiliates of UBS. The compensation of the analyst who prepared this document is determined exclusively by research management and senior
management (not including investment banking). Analyst compensation is not based on investment banking revenues; however, compensation may relate to the
revenues of UBS and/or its divisions as a whole, of which investment banking, sales and trading are a part, and UBS's subsidiaries, branches and affiliates as a whole.
For financial instruments admitted to trading on an EU regulated market: UBS AG, its affiliates or subsidiaries (excluding UBS Securities LLC) acts as a market maker or
liquidity provider (in accordance with the interpretation of these terms in the UK) in the financial instruments of the issuer save that where the activity of liquidity
provider is carried out in accordance with the definition given to it by the laws and regulations of any other EU jurisdictions, such information is separately disclosed in
this document. For financial instruments admitted to trading on a non-EU regulated market: UBS may act as a market maker save that where this activity is carried out in
the US in accordance with the definition given to it by the relevant laws and regulations, such activity will be specifically disclosed in this document. UBS may have issued
a warrant the value of which is based on one or more of the financial instruments referred to in the document. UBS and its affiliates and employees may have long or
short positions, trade as principal and buy and sell in instruments or derivatives identified herein; such transactions or positions may be inconsistent with the opinions
expressed in this document.
Options and futures are not suitable for all investors, and trading in these instruments is considered risky and may be appropriate only for sophisticated investors. Prior to
buying or selling an option, and for the complete risks relating to options, you must receive a copy of "Characteristics and Risks of Standardized Options". You may read
the document at https://www.theocc.com/about/publications/character-risks.js… or ask your financial advisor for a copy.
Investing in structured investments involves significant risks. For a detailed discussion of the risks involved in investing in any particular structured investment, you must
read the relevant offering materials for that investment. Structured investments are unsecured obligations of a particular issuer with returns linked to the performance of
an underlying asset. Depending on the terms of the investment, investors could lose all or a substantial portion of their investment based on the performance of the
underlying asset. Investors could also lose their entire investment if the issuer becomes insolvent. UBS Financial Services Inc. does not guarantee in any way the
obligations or the financial condition of any issuer or the accuracy of any financial information provided by any issuer. Structured investments are not traditional
investments and investing in a structured investment is not equivalent to investing directly in the underlying asset. Structured investments may have limited or no
liquidity, and investors should be prepared to hold their investment to maturity. The return of structured investments may be limited by a maximum gain, participation
rate or other feature. Structured investments may include call features and, if a structured investment is called early, investors would not earn any further return and may
not be able to reinvest in similar investments with similar terms. Structured investments include costs and fees which are generally embedded in the price of the
investment. The tax treatment of a structured investment may be complex and may differ from a direct investment in the underlying asset. UBS Financial Services Inc.
and its employees do not provide tax advice. Investors should consult their own tax advisor about their own tax situation before investing in any securities.
Important Information About Sustainable Investing Strategies: Sustainable investing strategies aim to consider and incorporate environmental, social and
governance (ESG) factors into investment process and portfolio construction. Strategies across geographies and styles approach ESG analysis and incorporate the
findings in a variety of ways. Incorporating ESG factors or Sustainable Investing considerations may inhibit the portfolio manager’s ability to participate in certain
investment opportunities that otherwise would be consistent with its investment objective and other principal investment strategies. The returns on a portfolio consisting
primarily of sustainable investments may be lower or higher than portfolios where ESG factors, exclusions, or other sustainability issues are not considered by the
portfolio manager, and the investment opportunities available to such portfolios may differ. Companies may not necessarily meet high performance standards on all
aspects of ESG or sustainable investing issues; there is also no guarantee that any company will meet expectations in connection with corporate responsibility,
sustainability, and/or impact performance.
Within the past 12 months UBS Switzerland AG, its affiliates or subsidiaries may have received or provided investment services and activities or ancillary services as per
MiFID II which may have given rise to a payment or promise of a payment in relation to these services from or to this company.
If you require detailed information on disclosures of interest or conflict of interest as required by Market Abuse Regulation please contact the mailbox
[e-mail]. Please note that e-mail communication is unsecured.
External Asset Managers / External Financial Consultants: In case this research or publication is provided to an External Asset Manager or an External Financial
Consultant, UBS expressly prohibits that it is redistributed by the External Asset Manager or the External Financial Consultant and is made available to their clients and/or
third parties.
Distributed to US persons by UBS Financial Services Inc. or UBS Securities LLC, subsidiaries of UBS AG. UBS Switzerland AG, UBS Europe SE, UBS Bank, S.A., UBS Brasil
Administradora de Valores Mobiliarios Ltda, UBS Asesores Mexico, S.A. de C.V., UBS Securities Japan Co., Ltd, UBS Wealth Management Israel Ltd and UBS Menkul
Degerler AS are affiliates of UBS AG. UBS Financial Services Incorporated of Puerto Rico is a subsidiary of UBS Financial Services Inc. UBS Financial Services Inc. accepts
responsibility for the content of a report prepared by a non-US affiliate when it distributes reports to US persons. All transactions by a US person in the
securities mentioned in this report should be effected through a US-registered broker dealer affiliated with UBS, and not through a non-US affiliate. The
contents of this report have not been and will not be approved by any securities or investment authority in the United States or elsewhere. UBS
Financial Services Inc. is not acting as a municipal advisor to any municipal entity or obligated person within the meaning of Section 15B of the Securities
Exchange Act (the "Municipal Advisor Rule") and the opinions or views contained herein are not intended to be, and do not constitute, advice within the
meaning of the Municipal Advisor Rule.
Austria: This publication is not intended to constitute a public offer under Austrian law. It is distributed only for information purposes to clients of UBS Europe SE,
Niederlassung Österreich, with place of business at Wächtergasse 1, A-1010 Wien. UBS Europe SE, Niederlassung Österreich is subject to the joint supervision of the
European Central Bank ("ECB"), the German Central Bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für
Finanzdienstleistungsaufsicht), as well as of the Austrian Financial Market Authority (Finanzmarktaufsicht, FMA), to which this publication has not been submitted for
approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. Bahrain: UBS is a Swiss
bank not licensed, supervised or regulated in Bahrain by the Central Bank of Bahrain and does not undertake banking or investment business activities in Bahrain.
Therefore, clients have no protection under local banking and investment services laws and regulations. Canada: The information contained herein is not, and under no
circumstances is to be construed as, a prospectus, an advertisement, a public offering, an offer to sell securities described herein, solicitation of an offer to buy securities
described herein, in Canada or any province or territory thereof. Any offer or sale of the securities described herein in Canada will be made only under an exemption
from the requirements to file a prospectus with the relevant Canadian securities regulators and only by a dealer properly registered under applicable securities laws or,
alternatively, pursuant to an exemption from the dealer registration requirement in the relevant province or territory of Canada in which such offer or sale is made.
Under no circumstances is the information contained herein to be construed as investment advice in any province or territory of Canada and is not tailored to the needs
of the recipient. To the extent that the information contained herein references securities of an issuer incorporated, formed or created under the laws of Canada or a
province or territory of Canada, any trades in such securities must be conducted through a dealer registered in Canada or, alternatively, pursuant to a dealer registration
exemption. No securities commission or similar regulatory authority in Canada has reviewed or in any way passed upon these materials, the information contained herein
Expert Call 24 February 2021
 18
or the merits of the securities described herein and any representation to the contrary is an offence. In Canada, this publication is distributed by UBS Investment
Management Canada Inc. China: This research report is neither intended to be distributed to PRC investors nor to provide securities investment consultancy services
within the territory of PRC. Czech Republic: UBS is not a licensed bank in the Czech Republic and thus is not allowed to provide regulated banking or investment
services in the Czech Republic. Please notify UBS if you do not wish to receive any further correspondence. Denmark: This publication is not intended to constitute a
public offer under Danish law. It is distributed only for information purposes to clients of UBS Europe SE, Denmark Branch, filial af UBS Europe SE, with place of business
at Sankt Annae Plads 13, 1250 Copenhagen, Denmark, registered with the Danish Commerce and Companies Agency, under No. 38 17 24 33. UBS Europe SE,
Denmark Branch, filial af UBS Europe SE is subject to the joint supervision of the European Central Bank ("ECB"), the German Central Bank (Deutsche Bundesbank), the
German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Danish Financial Supervisory Authority
(Finanstilsynet), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a
Societas Europaea, duly authorized by the ECB. Egypt: Securities or other investment products are not being offered or sold by UBS to the public in Egypt and they have
not been and will not be registered with the Egyptian Financial Supervisory Authority. France: This publication is distributed by UBS (France) S.A., French "société
anonyme" with share capital of € 132.975.556, 69, boulevard Haussmann F-75008 Paris, R.C.S. Paris B 421 255 670, to its clients and prospects. UBS (France) S.A. is a
provider of investment services duly authorized according to the terms of the "Code Monétaire et Financier", regulated by French banking and financial authorities as
the "Autorité de Contrôle Prudentiel et de Résolution." Germany: This publication is not intended to constitute a public offer under German law. It is distributed only
for information purposes to clients of UBS Europe SE, Germany, with place of business at Bockenheimer Landstrasse 2-4, 60306 Frankfurt am Main. UBS Europe SE is a
credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the European Central Bank ("ECB"), and supervised by the ECB,
the German Central Bank (Deutsche Bundesbank) and the German Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), to
which this publication has not been submitted for approval. Greece: UBS Switzerland AG and its affiliates (UBS) are not licensed as a bank or financial institution under
Greek legislation and do not provide banking and financial services in Greece. Consequently, UBS provides such services from branches outside of Greece, only. This
document may not be considered as a public offering made or to be made to residents of Greece. Hong Kong: This publication is distributed to clients of UBS AG Hong
Kong Branch by UBS AG Hong Kong Branch, a licensed bank under the Hong Kong Banking Ordinance and a registered institution under the Securities and Futures
Ordinance. UBS AG Hong Kong Branch is incorporated in Switzerland with limited liability. Indonesia, Malaysia, Phillipines, Thailand: This material was provided to
you as a result of a request received by UBS from you and/or persons entitled to make the request on your behalf. Should you have received the material erroneously,
UBS asks that you kindly destroy/delete it and inform UBS immediately. Any and all advice provided and/or trades executed by UBS pursuant to the material will only
have been provided upon your specific request or executed upon your specific instructions, as the case may be, and may be deemed as such by UBS and you. The
material may not have been reviewed, approved, disapproved or endorsed by any financial or regulatory authority in your jurisdiction. The relevant investments will be
subject to restrictions and obligations on transfer as set forth in the material, and by receiving the material you undertake to comply fully with such restrictions and
obligations. You should carefully study and ensure that you understand and exercise due care and discretion in considering your investment objective, risk appetite and
personal circumstances against the risk of the investment. You are advised to seek independent professional advice in case of doubt. India: UBS Securities India Private
Ltd. (Corporate Identity Number U67120MH1996PTC097299) 2/F, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai (India) 400051. Phone:
[phone]. It provides brokerage services bearing SEBI Registration Number INZ000259830; merchant banking services bearing SEBI Registration Number:
INM000010809 and Research Analyst services bearing SEBI Registration Number: INH000001204. UBS AG, its affiliates or subsidiaries may have debt holdings or
positions in the subject Indian company/companies. Within the past 12 months, UBS AG, its affiliates or subsidiaries may have received compensation for non-investment
banking securities-related services and/or non-securities services from the subject Indian company/companies. The subject company/companies may have been a
client/clients of UBS AG, its affiliates or subsidiaries during the 12 months preceding the date of distribution of the research report with respect to investment banking
and/or non-investment banking securities-related services and/or non-securities services. With regard to information on associates, please refer to the Annual Report at:
http://www.ubs.com/global/en/about_ubs/investor_relations/an… Israel: UBS is a premier global financial firm offering wealth management, asset
management and investment banking services from its headquarters in Switzerland and its operations in over 50 countries worldwide to individual, corporate and
institutional investors. In Israel, UBS Switzerland AG is registered as Foreign Dealer in cooperation with UBS Wealth Management Israel Ltd., a wholly owned UBS
subsidiary. UBS Wealth Management Israel Ltd. is a Portfolio Manager licensee which engages also in Investment Marketing and is regulated by the Israel Securities
Authority. This publication is intended for information only and is not intended as an offer to buy or solicitation of an offer. Furthermore, this publication is not intended
as an investment advice and/or investment marketing and is not replacing any investment advice and/or investment marketing provided by the relevant licensee which is
adjusted to each person needs. No action has been, or will be, taken in Israel that would permit an offering of the product(s) mentioned in this document or a
distribution of this document to the public in Israel. In particular, this document has not been reviewed or approved by the Israeli Securities Authority. The product(s)
mentioned in this document is/are being offered to a limited number of sophisticated investors who qualify as one of the investors listed in the first supplement to the
Israeli Securities Law, 5728-1968. This document may not be reproduced or used for any other purpose, nor be furnished to any other person other than those to whom
copies have been sent. Anyone who purchases the product(s) mentioned herein shall do so for its own benefit and for its own account and not with the aim or intention
of distributing or offering the product(s) to other parties. Anyone who purchases the product(s) shall do so in accordance with its own understanding and discretion and
after it has received any relevant financial, legal, business, tax or other advice or opinion required by it in connection with such purchase(s). The word "advice" and/or
any of its derivatives shall be read and construed in conjunction with the definition of the term "investment marketing" as defined under the Israeli Regulation of
Investment Advice, Investment Marketing and Portfolio Management Law, 1995.Italy: This publication is not intended to constitute a public offer under Italian law. It is
distributed only for information purposes to clients of UBS Europe SE, Succursale Italia, with place of business at Via del Vecchio Politecnico, 3-20121 Milano. UBS
Europe SE, Succursale Italia is subject to the joint supervision of the European Central Bank ("ECB"), the German Central Bank (Deutsche Bundesbank), the German
Federal Financial Services Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Bank of Italy (Banca d’Italia) and the Italian Financial
Markets Supervisory Authority (CONSOB - Commissione Nazionale per le Società e la Borsa), to which this publication has not been submitted for approval. UBS Europe
SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. Jersey: UBS AG, Jersey Branch, is regulated and
authorized by the Jersey Financial Services Commission for the conduct of banking, funds and investment business. Where services are provided from outside Jersey,
they will not be covered by the Jersey regulatory regime. UBS AG, Jersey Branch is a branch of UBS AG a public company limited by shares, incorporated in Switzerland
whose registered offices are at Aeschenvorstadt 1, CH-4051 Basel and Bahnhofstrasse 45, CH 8001 Zurich. UBS AG, Jersey Branch's principal place business is 1, IFC
Jersey, St Helier, Jersey, JE2 3BX. Luxembourg: This publication is not intended to constitute a public offer under Luxembourg law. It is distributed only for information
purposes to clients of UBS Europe SE, Luxembourg Branch, with place of business at 33A, Avenue J. F. Kennedy, L-1855 Luxembourg. UBS Europe SE, Luxembourg
Branch is subject to the joint supervision of the European Central Bank ("ECB"), the German Central bank (Deutsche Bundesbank), the German Federal Financial Services
Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Luxembourg supervisory authority (Commission de Surveillance du Secteur
Financier), to which this publication has not been submitted for approval. UBS Europe SE is a credit institution constituted under German law in the form of a Societas
Europaea, duly authorized by the ECB. Mexico: This information is distributed by UBS Asesores México, S.A. de C.V. ("UBS Asesores"), an affiliate of UBS Switzerland
AG, incorporated as a non-independent investment advisor under the Securities Market Law due to the relation with a Foreign Bank. UBS Asesores is a regulated entity
and it is subject to the supervision of the Mexican Banking and Securities Commission ("CNBV"), which exclusively regulates UBS Asesores regarding the rendering of
portfolio management, as well as on securities investment advisory services, analysis and issuance of individual investment recommendations, so that the CNBV has no
surveillance faculties nor may have over any other service provided by UBS Asesores. UBS Asesores is registered before CNBV under Registry number 30060. You are
being provided with this UBS publication or material because you have indicated to UBS Asesores that you are a Sophisticated Qualified Investor located in Mexico. The
compensation of the analyst(s) who prepared this report is determined exclusively by research management and senior management of any entity of UBS Group to
which such analyst(s) render services. Nigeria: UBS Switzerland AG and its affiliates (UBS) are not licensed, supervised or regulated in Nigeria by the Central Bank of
Nigeria or the Nigerian Securities and Exchange Commission (SEC) and do not undertake banking or investment business activities in Nigeria. The investment products
mentioned in this material are not being offered or sold by UBS to the public in Nigeria and they have not been submitted for approval nor registered with the Nigerian
SEC. If you are interested in products of this nature, please let us know and we will direct you to someone who can advise you. The investment products mentioned in
this material are not being directed to, and are not being made available for subscription by any persons within Nigeria other than the selected investors to whom the
offer materials have been addressed as a private sale or domestic concern within the exemption and meaning of Section 69(2) of the Investments and Securities Act,
2007 (ISA). Poland: UBS is a premier global financial services firm offering wealth management services to individual, corporate and institutional investors. UBS is
established in Switzerland and operates under Swiss law and in over 50 countries and from all major financial centres. UBS Switzerland AG is not licensed as a bank or as
an investment firm under Polish legislation and is not permitted to provide banking and financial services in Poland. Portugal: UBS Switzerland AG is not licensed to
conduct banking and financial activities in Portugal nor is UBS Switzerland AG supervised by the portuguese regulators (Bank of Portugal "Banco de Portugal" and
Portuguese Securities Exchange Commission "Comissão do Mercado de Valores Mobiliários"). Russia: This document or information contained therein is for information
purposes only and constitute neither a public nor a private offering, is not an invitation to make offers, to sell, exchange or otherwise transfer any financial instruments
in the Russian Federation to or for the benefit of any Russian person or entity and does not constitute an advertisement or offering of securities in the Russian Federation
within the meaning of Russian securities laws. Singapore: This material was provided to you as a result of a request received by UBS from you and/or persons entitled to
make the request on your behalf. Should you have received the material erroneously, UBS asks that you kindly destroy/delete it and inform UBS immediately. Clients of
UBS AG Singapore branch are asked to please contact UBS AG Singapore branch, an exempt financial adviser under the Singapore Financial Advisers Act (Cap. 110) and
Expert Call 24 February 2021
 19
a wholesale bank licensed under the Singapore Banking Act (Cap. 19) regulated by the Monetary Authority of Singapore, in respect of any matters arising from, or in
connection with, the analysis or report. Spain: This publication is is not intended to constitute a public offer under Spanish law. It is distributed only for information
purposes to clients of UBS Europe SE, Sucursal en España, with place of business at Calle María de Molina 4, C.P. 28006, Madrid. UBS Europe SE, Sucursal en España is
subject to the joint supervision of the European Central Bank ("ECB"), the German Central bank (Deutsche Bundesbank), the German Federal Financial Services
Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht), as well as of the Spanish supervisory authority (Banco de España), to which this publication has
not been submitted for approval. Additionally it is authorized to provide investment services on securities and financial instruments, regarding which it is supervised by
the Comisión Nacional del Mercado de Valores as well. UBS Europe SE, Sucursal en España is a branch of UBS Europe SE, a credit institution constituted under German
law in the form of a Societas Europaea, duly authorized by the ECB. Sweden: This publication is not intended to constitute a public offer under Swedish law. It is
distributed only for information purposes to clients of UBS Europe SE, Sweden Bankfilial, with place of business at Regeringsgatan 38, 11153 Stockholm, Sweden,
registered with the Swedish Companies Registration Office under Reg. No 516406-1011. UBS Europe SE, Sweden Bankfilial is subject to the joint supervision of the
European Central Bank ("ECB"), the German Central bank (Deutsche Bundesbank), the German Federal Financial Services Supervisory Authority (Bundesanstalt für
Finanzdienstleistungsaufsicht), as well as of the Swedish supervisory authority (Finansinspektionen), to which this publication has not been submitted for approval. UBS
Europe SE is a credit institution constituted under German law in the form of a Societas Europaea, duly authorized by the ECB. Taiwan: This material is provided by UBS
AG, Taipei Branch in accordance with laws of Taiwan, in agreement with or at the request of clients/prospects. Turkey: No information in this document is provided for
the purpose of offering, marketing and sale by any means of any capital market instruments and services in the Republic of Turkey. Therefore, this document may not be
considered as an offer made or to be made to residents of the Republic of Turkey in the Republic of Turkey. UBS Switzerland AG is not licensed by the Turkish Capital
Market Board (the CMB) under the provisions of the Capital Market Law (Law No. 6362). Accordingly neither this document nor any other offering material related to
the instruments/services may be utilized in connection with providing any capital market services to persons within the Republic of Turkey without the prior approval of
the CMB. However, according to article 15 (d) (ii) of the Decree No. 32 there is no restriction on the purchase or sale of the instruments by residents of the Republic of
Turkey. United Arab Emirates : UBS is not licensed in the UAE by the Central Bank of UAE or by the Securities & Commodities Authority. The UBS AG Dubai Branch is
licensed in the DIFC by the Dubai Financial Services Authority as an authorised firm. United Kingdom: This document is issued by UBS Wealth Management, a division
of UBS AG which is authorised and regulated by the Financial Market Supervisory Authority in Switzerland. In the United Kingdom, UBS AG is authorised by the
Prudential Regulation Authority and is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details
about the extent of regulation by the Prudential Regulation Authority are available from us on request. A member of the London Stock Exchange. This publication is
distributed to retail clients of UBS Wealth Management. Ukraine: UBS is not registered and licensed as a bank/financial institution under Ukrainian legislation and does
not provide banking and other financial services in Ukraine. UBS has not made and will not make any offer of the mentioned products to the public in Ukraine. No
action has been taken to authorize an offer of the mentioned products to the public in Ukraine and the distribution of this document shall not constitute financial
services for the purposes of the Law of Ukraine "On Financial Services and State Regulation of Financial Services Markets" dated 12 July 2001. Accordingly, nothing in
this document or any other document, information or communication related to the mentioned products shall be interpreted as containing an offer or invitation to offer,
or solicitation of securities in the territory of Ukraine. Electronic communication must not be considered as an offer to enter into an electronic agreement or electronic
instrument within the meaning of the Law of Ukraine "On Electronic Commerce" dated 3 September 2015. This document is strictly for private use by its holder and
may not be passed on to third parties or otherwise publicly distributed.
© UBS 2021. The key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.


[Tirolesi]

Antwort auf Beitrag Nr.: 67.185.237 von Tirolesi am 24.02.21 20:30:58

HAB gerade nochmals nachgesehen,
waren nicht alle um CAD 0,15 sondern auch welche zu CAD 0,40 dabei

[Tirolesi]

NAJA das ist doch Legetim von Don,
wird doch von jedem Managment so gemacht,

man verkauft Aktien um CAD 0,50 - CAD 0,70

löst mit diesen Einnahmen die Warrants ein um CAD 0,15

aus diesem Grunde sollte man ab und zu einem Placement teilnehmen

[Hottest]

Antwort auf Beitrag Nr.: 67.183.122 von Mitch17 am 24.02.21 18:47:55

Seit 18.02.

https://stockhouse.com/companies/insiders?symbol=v.mdl